0001209191-24-005522.txt : 20240503
0001209191-24-005522.hdr.sgml : 20240503
20240503205105
ACCESSION NUMBER: 0001209191-24-005522
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240503
FILED AS OF DATE: 20240503
DATE AS OF CHANGE: 20240503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ZANTE GREG
CENTRAL INDEX KEY: 0001264949
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 24915292
MAIL ADDRESS:
STREET 1: C/O SANGAMO BIOSCIENCES, INC STE-A-100
STREET 2: POINT RICHMOND TECH, 501 CANAL BLVD,
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-05-03
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001264949
ZANTE GREG
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
1
Common Stock, par value $0.00001 per share
2024-05-03
4
M
0
4249
4.68
A
211610
D
Common Stock, par value $0.00001 per share
2024-05-03
4
M
0
30000
4.88
A
241610
D
Common Stock, par value $0.00001 per share
2024-05-03
4
S
0
3101
73.4881
D
238509
D
Common Stock, par value $0.00001 per share
2024-05-03
4
S
0
45570
74.4447
D
192939
D
Common Stock, par value $0.00001 per share
2024-05-03
4
S
0
17238
75.4868
D
175701
D
Common Stock, par value $0.00001 per share
2024-05-03
4
S
0
847
76.0743
D
174854
D
Stock Option (Right to Buy)
4.68
2024-05-03
4
M
0
4249
0.00
D
2021-03-31
2030-03-31
Common Stock
4249
4251
D
Stock Option (Right to Buy)
4.88
2024-05-03
4
M
0
30000
0.00
D
2023-01-03
2032-01-03
Common Stock
30000
60000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.97 to $73.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.98 to $74.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.985 to $75.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.995 to $76.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date.
/s/ Michael Morneau as Attorney-in-Fact
2024-05-03